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Abstract 
Recent advances in near-infrared (NIR) fluorescence imaging enabled real-time intraoperative 
detection of bone metastases, bone growth, and tissue microcalcification. Pamidronate (PAM) has 
been widely used for this purpose because of its high binding affinity toward bone and remarkable 
therapeutic effects. Herein we describe the development of a series of PAM-conjugated NIR 
fluorophores that varied in net charges and hydrophobicity, and compared their bone targeting 
efficiency, biodistribution, and blood clearance. Since the targeting moiety, PAM, is highly nega-
tively charged but small, the overall in vivo bone targeting and biodistribution were mediated by the 
physicochemical properties of conjugated fluorophores. 
Key words: Near-infrared fluorophores, Bone targeting, Charge and hydrophobicity, Microcalci-
fication, Zwitterionic fluorophores. 
Introduction 
Phosphonate derivatives have been widely used 
as targeting and therapeutic agents for bone imaging 
and bony disease treatments [1,2]. Bisphosphonates 
are known to exhibit high affinity for bone surfaces 
minerals and calcium salts [3]. Bisphosphonates have 
also been used as a bone-targeting vector in a variety 
of contrast agents for the detection and therapy of 
numerous bone diseases [4-6]. Clinically bone tissue 
imaging is based almost exclusively on x-ray or radi-
ochemical methods. Recently the state-of-the-art im-
aging modalities such as computed tomography (CT), 
magnetic resonance imaging (MRI), single photon 
emission computed tomography (SPECT), positron 
emission tomography (PET), and their combinations 
have been used to detect changes in bone by using 
radioactive metal ions chelators conjugated to 
bone-binding bisphosphonates [7-10]. These method-
ologies have proven useful for diagnostic imaging; 
however, real-time imaging cannot be readily 
achieved using CT, MRI, SPECT or PET imaging. Re-
al-time in vivo optical imaging using near-infrared 
(NIR) fluorescent light has received considerable in-
terest in imaging of animal and human tissues in-
cluding nerve [11], vasculature [12,13], tissue perfu-
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sion [14,15], lymph nodes [16-19], ureter [20-22], bile 
duct [23,24], and various cancers [25-28]. Additionally 
the NIR window (650-900 nm) has minimized tissue 
scattering, absorption, and autofluorescence [29]; 
therefore, it has the potential to provide highly sensi-
tive, rapid, and non-radioactive bone imaging.  
Previously we have reported the development of 
bone-specific NIR fluorophores by conjugating con-
ventional dyes IRDye78 [30] and IRDye800-CW 
[31,32] with pamidronate (PAM). Although both 
Pam78 and Pam800 exhibit rapid and specific binding 
to hydroxyapatite (HA) in vitro and in vivo, the de-
tailed molecular effect of conjugated fluorophores on 
bone targeting potency and in vivo performance has 
not been investigated.  
Indeed, when conjugated with zwitterionic 
fluorophores, relatively large targeting ligands such 
as peptides and proteins were dominated by overall 
molecular charge and charge distribution, which 
played an important role to improve sig-
nal-to-background ratio (SBR) for fluorescence imag-
ing [12,25]. We have also been systematically probing 
the relationship among the hydrodynamic diameter, 
shape, charge, and hydrophobicity of NIR fluoro-
phores on in vivo targeting and biodistribution [33-35].  
In this study, we hypothesize that zwitterionic or 
positively charged NIR fluorophores may improve or 
change the in vitro and in vivo performance of targeted 
small molecule ligands. Bone-specific bisphosphonate 
ligand PAM was used to conjugate with three spec-
trally similar heptamethine NIR fluorophores, and 
their targeting performance was explored on the basis 
of the final physicochemical properties including net 
charge, hydrophobicity, and polarity. The optical 
property and in vitro HA-binding of PAM-NIR 
fluorophore were also performed systematically. 
Results  
Synthesis of PAM-NIR fluorophores. 
PAM-ZW800-1, PAM-CW800, and PAM-ZW800-3a 
were synthesized by conjugating the protected PAM 
with ZW800-1 [12], IRDye800-CW [32], and ZW800-3a 
[12], respectively. First, as shown in Fig. 1a, the tet-
ramethyl-protected pamidronate 6 was synthesized 
via a modified one-pot synthesis from our previously 
reported method [32]. The multi-step synthetic 
scheme initiated by reacting readily available 
Z-β-Alanine 1 with oxalyl chloride to produce an acyl 
chloride derivative 2 without isolation. In the follow-
ing one-pot Arbuzov reaction, the acyl chloride 2 was 
reacted with trimethylphosphite to yield a phosphite 
derivative 3. A second crucial Arbuzov reaction with 
dimethyl(trimethylsilyl)phosphite led to the for-
mation of the Cbz-protected tetramethylphosphonate 
5. After catalytic hydrogenolysis, the tetramethyl 
protected pamidronate 6 was obtained without any 
isomerization, a limitation of the previously pub-
lished method [31,32]. The conjugation of the NIR 
fluorophores ZW800-1, CW800, and ZW800-3a to 
compound 6 was completed by using dipyrroli-
dino(N-succinimidyloxy)carbenium hexafluoro-
phosphate (HSPyU) and N,N-diisopropylethylamine 
(DIEA) in dry dimethyl sulfoxide (DMSO). In the 
fluorophore conjugation reaction, hydrolysis of the 
four contained methyl groups using trimethylsilyl 
bromide in dimethylformamide (DMF) yielded 
PAM-ZW800-1, PAM-CW800, and PAM-ZW800-3a 
(see details in Materials and Methods). The final 
compounds were purified by preparative HPLC and 
analyzed by mass spectrometry (Supplementary Ma-
terial: Fig. S1). Prior to measurement of optical prop-
erties and in vivo performance, each PAM-NIR fluor-
ophore was purified to ≥ 90% as measured using a 
photodiode array (PDA) at 210 nm absorbance.  
Characterizations of PAM-NIR fluorophores. 
Physicochemical and optical properties of the synthe-
sized PAM-NIR fluorophores are summarized in Fig. 
1b and Supplementary Material: Fig. S2. By varying 
the side chains of the polymethine core, it was possi-
ble to systematically modify the electron resonance, 
hydrophobicity and polarity. The 3D structures dis-
play differences in charge and hydrophobicity dis-
tributions over the molecular surface. Because of the 
flexible “O” atom on the meso carbon, there is a 
roughly 60° angle between the cyanine skeleton and 
the phenoxy propionic acid group, after conjugation 
with the PAM. The partition coefficient (logD values 
at pH 7.4) reflects the decreased molecular hydro-
phobicity after PAM conjugation in the order of 
PAM-ZW800-3a (0.06), PAM-ZW800-1 (-4.22), and 
PAM-CW800 (-9.97). The conjugation of PAM with 
the heptamethine fluorophores had minimal impact 
on the spectral properties of each NIR fluorophore. 
All PAM-NIR fluorophores exhibited maximum ab-
sorption around 770 nm, maximum fluorescence 
emission ≥ 790 nm, and relatively high extinction co-
efficients and quantum yields in 100% serum, which 
together minimize tissue autofluorescence and max-
imize fluorescence signal during intraoperative im-
aging. 
In vitro calcium salt binding specificity. The 
specificity of PAM-ZW800-1, PAM-CW800, and 
PAM-ZW800-3a for hydroxyapatite (HA) over other 
calcium salts was determined using NIR fluorescence 
imaging. 5 µM of each PAM-NIR fluorophore was 
incubated with HA and calcium carbonate (CC), cal-
cium oxalate (CO), calcium phosphate (CP), and cal-
cium pyrophosphate (CPP) for 30 min at room tem-
perature with constant shaking, then washed 3 times 
with a 100-fold excess of phosphate-buffered saline 
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(PBS). As shown in Fig. 2, all the fluorophores 
demonstrated strong affinity for HA compared to 
other calcium salts. In addition, PAM-ZW800-1 ex-
hibited higher SBR when binding to HA than the 
other two PAM fluorophore derivatives (Fig. 2). This 
increase in SBR for PAM-ZW800-1 and PAM-CW800 
over PAM-ZW800-3a can be attributed to the im-
proved calcium binding via salt formation through 
the phenyl sulfonate moieties in the fluorophore 
backbone [36,37]. In addition, the hydroxyl group of 
HA contributes to the formation of strong hydrogen 
bonds with anions of fluorophores, which increased 
binding affinity significantly [36]. Of note, 
PAM-ZW800-1 had 8-fold higher specificity toward 
HA over other calcium salts, and permits NIR fluo-
rescence detection of HA with high sensitivity.  
 
 
Figure 1. Synthesis and characterization of PAM-ZW800-1, PAM-CW800 and PAM-ZW800-3a NIR fluorophores. (a) Synthetic scheme for compound 6 
and PAM-NIR fluorophores. (b) Chemical structures and physicochemical properties of NIR fluorophores having systematically varying net charges. 3D 
molecular structure was depicted using MarvinSketch 6.2.2 (ChemAxon). Red: negative charge; blue: positive charge; and gray: hydrophobicity. LogD = 
partition coefficient; PSA = polar surface area; QY = quantum yield; ε = extinction coefficient. 
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Figure 2. Specificity of PAM-ZW800-1, PAM-CW800 and PAM-ZW800-3a for hydroxyapatite (HA) over other calcium salts. Each fluorophore was well 
mixed with calcium salts for 30 min and washed with excess of PBS prior to NIR fluorescence imaging. SBR was calculated by the fluorescence intensity of 
each fluorophore sample versus the signal intensity of each control sample (n = 3, mean ± s.d.). ***P < 0.001. Abbreviations: CC = calcium carbonate; CO 
= calcium oxalate; HA = hydroxyapatite; CP = calcium phosphate and CPP = calcium pyrophosphate. 
 
In vivo NIR fluorescence imaging of bone tis-
sue in mice. 10 nmol of each PAM-NIR fluorophore 
was administered intravenously to mice and allowed 
4 h to distribute and clear prior to fluorescence imag-
ing. As shown in Fig. 3a, PAM-CW800 provided 
high-sensitivity in the normal bones including jaw-
bone, sternum, ribs, spinal cord, and tailbones. Inter-
estingly PAM-ZW800-1 signals were found both in 
bone and cartilage tissues including knee joints, rib 
cage, and intervertebral discs. The increased cartilage 
signal (arrowheads) is likely due to the cartilage af-
finity of quaternary ammonium moiety in the 
ZW800-1 fluorophore [38]. One the other hand, 
PAM-ZW800-3a fluorescent signals were found not 
only in the bone and cartilage, but also in the liver 
with a high portion due to its high hydrophobicity. 
Control experiments were also performed with NIR 
fluorophores without PAM to show the inherent bio-
distribution and clearance of unconjugated fluoro-
phores [12]. ZW800-1 showed high renal clearance, 
while CW800 and ZW800-3a represented elevated 
nonspecific background signals in the liver and skin 
(Supplementary Material: Fig. S3).  
Blood half-life and organ biodistribution. 
Blood half-life of each PAM-NIR fluorophore was 
measured during the 4 h biodistribution and clearance 
time (Fig. 3b). The elimination half-life (t1/2β) of 
PAM-ZW800-1 and PAM-CW800 were similar and 
found to be 40 min and 47 min, respectively. 
PAM-ZW800-3a showed an extended t1/2 of 68 min, 
which was longer than that of fluorophore itself (28 
min) due to the additional negative charges following 
conjugation to the PAM molecule [12]. As shown in 
Fig. 3c, PAM-ZW800-1 was eliminated from the body 
through renal clearance with minimal non-specific 
uptake in other organs and tissues, while specific flu-
orescence signal was seen in bone and cartilage. 
PAM-CW800 demonstrated bone specific targeting, 
however the uptake in skin (***P < 0.001) and intestine 
(*P < 0.05) was much higher than the other two agents. 
As demonstrated through fluorescence imaging in 
Fig. 3a, PAM-ZW800-3a showed bone targeting fluo-
rescence signal, but also demonstrated significant 
uptake in the liver (***P < 0.001). These results establish 
the relationship between the surface charge and hy-
drophobicity of targeted small molecule fluorophores 
and the biodistribution, blood half-life, organ reten-
tion and clearance route following intravenous ad-
ministration in vivo. 
Discussion 
Physicochemical properties of small molecules 
determine the fate of an intravenously injected 
fluorophore in the body [28,33-35]. Total surface 
charge and hydrophobicity are of significant im-
portance to design targeted contrast agents for tis-
sue-specific imaging and optimized in vivo perfor-
mance [25]. PAM is a negatively charged small mol-
ecule with a molecular weight of 235.07 Da, Polar 
surface area (PSA) of 161.31 Å2, and logD of -6.92 at 
physiological pH. Comparison of the net charge at pH 
7.4 between free fluorophores and PAM-NIR fluoro-
phore conjugates were performed by using 
MarvinSketch 6.2.2 software, and PAM imparts an 
additional net charge of -3 to the total molecular 
charge and significantly increases the overall hydro-
philicity and polarity. However, as demonstrated in 
the current work the optical properties of the conju-
gated NIR fluorophores were unchanged in the 
presence of PAM. When the in vitro specificity was 
examined, all PAM-NIR fluorophores demonstrated 
strong binding affinity to HA with significantly 
higher SBR by comparison to the other calcium salts. 
This indicates that PAM plays a dominant role in the 
binding and the changes in physicochemical proper-
ties have limited impact on the functionality of the 
ligand. Furthermore, the intraoperative mouse imag-
ing clearly indicates all PAM conjugated NIR fluoro-
phores had strong binding affinity for bone. 
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Figure 3. In vivo biodistribution and bone specific imaging using PAM-NIR fluorophores in mice. (a) 10 nmol (0.4 mg/kg) of each PAM-NIR conjugate was 
injected intravenously into 25 g nude mice 4 h prior to imaging. Arrowheads indicate cartilage tissues. Li = liver, scale bars = 1 cm. All NIR fluorescence 
images were collected with the same exposure time and are displayed with identical normalization. (b) Blood clearance (%ID/g) and blood half-life (mean 
± 95% confidence intervals) in mice (n = 3, mean ± s.d.). (c) Organ biodistribution in mice. Animals were sacrificed at 30, 60, 90, 120, 180, and 240 min, and 
major tissues and organs were resected and imaged (n = 3, mean ± s.d.). *P < 0.05, **P < 0.01, and ***P < 0.001. 
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Although PAM maintained its ligand function-
ality in vitro and in vivo, the biodistribution and 
clearance patterns of the conjugates were strongly 
governed by the NIR fluorophores because the size of 
the targeting ligand is smaller than that of the effector 
domain. Since ZW800-1 has the balanced surface 
charge and relative hydrophilic property, 
PAM-ZW800-1 excreted to urine after active uptake 
into the skeleton. Additionally, the presence of 2 
quaternary ammonium cations in the ZW800-1 mol-
ecule also led the molecule to accumulate in cartilage 
due to the strong affinity of these positively charge 
moiety for the negatively charged glycosaminogly-
cans [38]. The negatively charged PAM-CW800 (-6) 
accumulated in skin, liver, and intestines in addition 
to the strong uptake in bone tissue 4 h 
post-intravenous injection, which was enhanced by 
the presence of three phenyl sulfonate groups on the 
surface of the molecule [36,37]. In the case of 
PAM-ZW800-3a, the absence of phenyl sulfonate 
groups and presence of strong quaternary ammonium 
cations enhanced the affinity of ZW800-3a for carti-
lage. In addition, the logD value at pH 7.4 for 
PAM-ZW800-3a increased to 0.06, which resulted in 
high nonspecific uptake in the liver, spleen, and skin. 
In conclusion, three bone-targeting nanoprobes 
that varied in net charges and hydrophobicity were 
developed systematically by conjugating PAM on the 
backbone of different NIR fluorophores. The in vivo 
data prove that overall molecular net charge and hy-
drophobicity of targeted fluorophores play a signifi-
cant role in the biodistribution, blood half-life, organ 
accumulation and clearance route of intravenously 
administered contrast agents. Thus the overall mo-
lecular net charge and hydrophobicity will also have 
strong influence on the targetability, specificity and 
fluorophore selection for targeted contrast agents and 
is therefore an important consideration in the devel-
opment of next generation organ-specific imaging 
probes and therapeutic agents. However, it should be 
noted that the introduction of multivalent ligands on 
the surface of small molecules or nanoparticles would 
change the pattern of biodistribution significantly 
because the conjugated ligands will be dominant over 
the effector domain [28,33].  
Materials and Methods 
Reagents: All chemicals were American Chemi-
cal Society grade or higher and commercially availa-
ble unless noted otherwise. IRDye800CW-NHS was 
purchased from LI-COR (Lincoln, NE) and stored 
under nitrogen at –80°C. HPLC-grade solvents were 
purchased from Fisher Scientific (Pittsburgh, PA, 
USA) and Sigma-Aldrich (Saint Louis, MO, USA). 
Ultra dry DMSO was purchased from Acros Organics 
(Geel, Belgium). 
NMR Spectroscopy: NMR spectra were rec-
orded on a Varian 400 MHz NMR system. Chemical 
shifts, d, are represented in part per million (ppm) 
and coupling constants, J, in Hertz (Hz). Tetrame-
thylsilane (TMS, 0 ppm) was used as the internal 
standard for proton NMR. 
One-pot synthesis of protected bisphosphonate 
5: 3-[(benzyloxycarbonyl)amino]-propionic acid (4.46 
g, 20 mmol) was dissolved in 40 mL of dichloro-
methane and cooled down to 0° C under a nitrogen 
atmosphere. Oxalyl Chloride (8.57 mL, 100 mmol) 
was added and the reaction mixture was stirred at 0° 
C for 30 minutes, followed by stirring at room tem-
perature for 6 h. The solvent was evaporated under 
vacuum and washed with additional dichloro-
methane to remove the excess oxalyl chloride. The 
product was dried under vacuum (0.001 Torr) for 2 h 
and trimethyl phosphite (2.73 g, 22 mmol) was added 
dropwise at 0° C over 5 minutes. The resulting mix-
ture was allowed to reach room temperature after 
which it was stirred for an additional 15 minutes. 
Following removal of the volatile material under re-
duced pressure, dimethyl trimethylsilyl phosphite (4 
g, 22 mmol) in dichloromethane (20 mL) was added at 
0° C under a nitrogen atmosphere. The reaction mix-
ture was stirred at room temperature for 6 h. The 
solvent was evaporated under vacuum and the re-
sulting mixture was treated with 3 M hydrochloric 
acid (HCl, 40 mL) and methanol (20 mL) at room 
temperature for 2 h. The reaction mixture was ex-
tracted with ether (3 x 30 mL), washed with water and 
brine, and then dried over magnesium sulfate 
(MgSO4). The volatile organic solvent was evaporated 
under reduced pressure and washed with hexane (3 x 
10 mL) to give dimethyl [3-(Benzyloxycarbony-
lamino)-1-(dimethoxyphosphoryl)-1-hydroxypropyl] 
phosphonate 5 as pale yellow oil (7.48 g, 88% yield). 
1H NMR (400 MHz, CD3OD) δ 2.25 (m, 2H), 3.50 (t, 
J=6.0 Hz, 2H), 3.83 (s, 12H), 5.07 (s, 2H), 5.25 (brs, 1H), 
5.61 (brs, 1H), 7.31-7.33 (m, 5H). Accurate mass TOF 
HRMS (m/z) [M+H]+ calculated for C15H26NO9P2, 
426.1083, found 426.1085.  
Synthesis of unprotected bisphosphonate 6: 
Dimethyl [3-(Benzyloxycarbonylamino)-1-(dimetho-
xyphosphoryl)-1-hydroxypropyl] phosphonate 5 (4.25 
g, 10 mmol) was placed in a 500-mL Parr bottle under 
nitrogen and dissolved in 50 mL of cold denatured 
methanol. Palladium on activated carbon (0.27 g, 10 
wt.%) was added carefully and the Parr shaker appa-
ratus was assembled. The reaction was shaken at 50 
psi hydrogen at room temperature until hydrogen 
uptake was complete (6-12 h). The palladium on ac-
tivated carbon was filtered over a Celite pad and the 
solvent was evaporated under reduced pressure to 
 Theranostics 2015, Vol. 5, Issue 6 
 
http://www.thno.org 
615 
give dimethyl [3-amino-1-(dimethoxyphosphoryl)-1- 
hydroxypropyl] phosphonate 6 as yellow solid (2.62 
g, 90% yield). 1H NMR (400 MHz, CD3OD) δ 1.33 (t, 
J=7.4 Hz, 2H), 2.38 (brs, 2H), 2.49 (m, 1H), 3.21 (m, 
2H), 3.30-3.90 (m, 12H). Accurate mass TOF HRMS 
(m/z) [M+H]+ calculated for C7H20NO7P2, 292.0715, 
found 292.0716. 
Synthesis of PAM-ZW800-1, PAM-CW800, and 
PAM-ZW800-3a: To a solution of 10 mg of the NIR 
fluorophore in 0.5 mL of anhydrous DMSO, 3 equiv-
alents (eq) of N,N-Diisopropylethylamine (DIEA) and 
1.5 eq of Dipyrrolidino (N-succinimidyloxy) carbe-
nium hexafluorophosphate (HSPyU) were added. The 
pH value of the mixture was maintained between 8-10 
by adding additional DIEA when required. The reac-
tion was stirred at room temperature in the dark for 2 
h followed by the addition of 2 eq. of compound 6. 
After stirring at room temperature in the dark for 4 h, 
the reaction mixture was poured over 5 mL ice-cold 
water and purified by reverse-phase HPLC to give 
compound 9 as the green solid after concentration 
under vacuum. 5 eq. Trimethylsilyl bromide were 
added slowly to a solution of 5 mg compound 9 in 0.2 
mL of dry DMF at 0 °C under nitrogen atmosphere. 
The reaction mixture was stirred at room temperature 
for 18 h in the dark and the solvent was evaporated 
off to dryness. Then 0.2 mL of CH3OH-H2O (4:1) was 
added to yield a bright green solution, which was 
stirred for 30 min at room temperature and purified 
by reverse-phase HPLC to give the PAM-NIR fluor-
ophores (compound 10) as the green solid. 
PAM-ZW800-1: green solid (3.7 mg, 79% yield), ac-
curate mass TOF HRMS (m/z) [M+2H]2+/2 calculated 
for C54H77N5O15P2S2 580.7161, found 580.7159. 
PAM-CW800, green solid (3.8 mg, 81% yield), accu-
rate mass TOF HRMS (m/z) [M-2H]2-/2 calculated for 
C49H61N3O21P2S4 , 608.6084, found [M+H]+ 608.6087. 
PAM-ZW800-3a, green solid (3.4 mg, 74% yield), ac-
curate mass TOF HRMS (m/z) [M+2H]2+/2 calculated 
for C54H77N5O9P2, 500.7593, found 500.7592. 
Reverse phase HPLC: HPLC purification of 
compounds was performed on a Waters (Milford, 
MA, USA) prepHPLC 150 ml fluid handling unit 
equipped with a manual injector (Rheodyme 3725i) 
and a 2487 dual wavelength absorbance detector out-
fitted with a semi-preparative flow cell. A flow split-
ter (Upchurch Scientific, Oak Harbor, WA, USA) di-
verted a portion of the eluate into an evaporative light 
scatter detector (ELSD, Richards Scientific, Novato, 
CA, USA) with the nebulizer modified to reduce band 
broadening at low flow rates while the other part 
flowed into a fraction collector. The ELSD was set to 
42 °C, with a nitrogen pressure at 3.5 bar and a gain of 
8. HPLC purification was completed using a Sym-
metry Prep C18 column (19 x 150 mm, 7 µm particle 
size) and a dual-wavelength absorbance detector (254 
and 700 nm). Solvent A was water with 10 mM TEAA 
and solvent B was absolute methanol. The purification 
utilized a linear gradient from 0% to 70% solvent B 
over 35 min. Mobile phase flow rate was 15 mL/min.  
ES-TOF mass spectroscopic analysis: The purity 
of all compounds was measured using ul-
tra-performance liquid chromatography (UPLC, Wa-
ters) combined with simultaneous ELSD, absorbance 
(photodiode array), fluorescence and electrospray 
time-of-flight (ES-TOF) mass spectrometry (MS). 
UPLC analyses were carried out using a Waters 
ACQUITY UPLC HSS C18 column (2.1x50 mm, 1.8 
µm) and Xevo G2 QTof detector connected to a PC 
with a MassLynx 4.1 workstation. The mobile phase 
was solvent A = 0.1% formic acid in water, solvent B = 
0.1% formic acid in acetonitrile with a linear gradient 
from 10% to 90% (from A to B for 5 minutes). The flow 
rate was 0.6 mL/min and all compounds were identi-
fied by mass to charge ratio.  
Optical and physicochemical property anal-
yses: All optical measurements were performed at 
37°C in 100% fetal bovine serum (FBS), buffered with 
50 mM HEPES, pH 7.4. The partition coefficient (logD 
at pH 7.4) of each fluorescent conjugate was calcu-
lated using JChem calculator plugins (ChemAxon, 
Budapest, Hungary). Fluorescence quantum yield 
(QY) was measured for each fluorescent conjugate 
using ICG in DMSO (QY 13%) as a calibration stand-
ard under conditions of matched absorbance at 765 
nm. Absorbance and fluorescence spectra for all fluo-
rescent conjugates were collected using online fiber-
optic HR2000 absorbance (200-1100 nm) and 
USB2000FL fluorescence (350-1,000 nm) spectrometers 
(Ocean Optics, Dunedin, FL) with NIR excitation 
provided by a 770 nm NIR laser diode light source 
(Electro Optical Components, Santa Rosa, CA). 
In vitro calcium salts specificity experiments: 
Calcium carbonate, calcium oxalate, hydroxyapatite, 
calcium phosphate and calcium pyrophosphate salts 
(25 mg/mL salts, 0.2-0.25 M calcium ions) were incu-
bated separately with 5 µM of PAM-ZW800-1, 
PAM-CW800 and PAM-ZW800-3a in PBS. The cal-
cium salts were vortexed continuously with the 
fluorophore conjugates at room temperature for 30 
min. The crystals, calcium salts, were washed three 
times with a 100-fold excess of PBS, centrifuged and 
visualized in 96-well plate using our fluorescence 
imaging system [37]. All NIR fluorescence images 
were collected at identical exposure times and are 
displayed with equal normalization.  
In vivo biodistribution and clearance: Animals 
were housed in an AAALAC-certified facility and 
were studied under the supervision of Beth Israel 
Deaconess Medical Center’s IACUC in accordance 
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with the approved institutional protocol (#101-2011). 
Male CD-1 mice weighing roughly 20 g were pur-
chased from Charles River Laboratories (Wilmington, 
MA) and male NCr nu/nu mice 5 to 6 weeks of age 
weighing 22 g ± 3 g were purchased from Taconic 
Farms (Germantown, NY). Animals were anesthe-
tized with 100 mg/kg ketamine and 10 mg/kg 
xylazine intraperitoneally (Webster Veterinary, Fort 
Devens, MA). 10 – 25 nmol (0.4 – 1.0 mg/kg) of the 
NIR fluorophore conjugate in saline were adminis-
tered intravenously, and animals were imaged with 
our real-time intraoperative imaging system as de-
scribed in detail previously [12,25]. For fluorescence 
excitation, 14 mWcm-2 of 745 to 779 nm-filtered light 
was used, and for emission, light was filtered using a 
800 to 848 nm band pass filter. For each experiment, 
camera exposure time and image normalization was 
held constant. To quantify the blood clearance rate 
and urinary excretion, intermittent sampling from the 
tail vein was performed over the 4 h period following 
intravenous administration. Approximately 10-20 µL 
of blood were collected using glass capillary tubes at 
the following time points: 0, 1, 2, 5, 10, 15, 30, 60, 90, 
120, 180, and 240 min. Custom intraoperative fluo-
rescence imaging system was used to measure the 
fluorescence intensity of each sample, and the con-
centration was calculated based on the image SBR 
using a standard curve for each fluorophore. To 
measure total body excretion in mice, animals were 
sacrificed at 30, 60, 90, 120, 180, and 240 min, and 
major tissues and organs were resected and imaged. 
Using capillary tubes, the amount of NIR fluorophore 
in each organ/tissue was quantified by measuring 
fluorescent intensity (photons/s/cm2/sr). 
Quantitative analysis: At each time point, the 
fluorescence and background intensity of a region of 
interest (ROI) over each tissue was quantified using 
custom imaging software and ImageJ v1.48 (NIH, 
Bethesda, MD). The signal-to-background ratio (SBR) 
was calculated as SBR = fluorescence/background, 
where background is the signal intensity of neigh-
boring tissues such as muscle or skin obtained over 
the period of imaging time. All NIR fluorescence im-
ages for a particular fluorophore were normalized 
identically for all conditions of an experiment. At least 
three animals were analyzed at each time point. A 
one-way ANOVA followed by Tukey’s multiple com-
parisons test were used to assess the statistical dif-
ferences between multiple groups. A P value of less 
than 0.05 was considered significant: *P < 0.05, **P < 
0.01, and ***P < 0.001. Results are presented as mean ± 
standard deviation (s.d.) where curve fitting was 
performed using Prism version 4.0a software 
(GraphPad, San Diego, CA). 
Supplementary Material 
Figures S1 - S3. 
http://www.thno.org/v05p0609s1.pdf 
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